Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UNF1

UPID:
MAGD2_HUMAN

ALTERNATIVE NAMES:
11B6; Breast cancer-associated gene 1 protein; Hepatocellular carcinoma-associated protein JCL-1; MAGE-D2 antigen

ALTERNATIVE UPACC:
Q9UNF1; A6NMX0; O76058; Q5BJF3; Q8NAL6; Q9H218; Q9P0U9; Q9UM52

BACKGROUND:
The protein Melanoma-associated antigen D2, with aliases such as 11B6 and Breast cancer-associated gene 1 protein, is pivotal in regulating key components of salt reabsorption in the kidneys. Its function is critical for the proper operation of the sodium chloride cotransporters SLC12A1 and SLC12A3 in the distal renal tubule.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Bartter syndrome 5, a disorder marked by severe salt wasting and hypokalemic metabolic alkalosis, MAGE-D2 represents a significant target for drug discovery efforts. The exploration of MAGE-D2's function and mechanisms offers promising avenues for developing novel treatments for related renal disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.